PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)

Detalles Bibliográficos
Autores principales: Zeidan, Amer M., Mosher, Karen, Souza, Sonia, Mirakhur, Beloo, Keer, Harold, Taylor, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429874/
http://dx.doi.org/10.1097/01.HS9.0000974892.81919.d4
_version_ 1785090820328652800
author Zeidan, Amer M.
Mosher, Karen
Souza, Sonia
Mirakhur, Beloo
Keer, Harold
Taylor, Jason
author_facet Zeidan, Amer M.
Mosher, Karen
Souza, Sonia
Mirakhur, Beloo
Keer, Harold
Taylor, Jason
author_sort Zeidan, Amer M.
collection PubMed
description
format Online
Article
Text
id pubmed-10429874
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104298742023-08-17 PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) Zeidan, Amer M. Mosher, Karen Souza, Sonia Mirakhur, Beloo Keer, Harold Taylor, Jason Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429874/ http://dx.doi.org/10.1097/01.HS9.0000974892.81919.d4 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Zeidan, Amer M.
Mosher, Karen
Souza, Sonia
Mirakhur, Beloo
Keer, Harold
Taylor, Jason
PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
title PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
title_full PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
title_fullStr PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
title_full_unstemmed PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
title_short PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
title_sort pb2021: phase 2 study of oral decitabine/cedazuridine in combination with magrolimab for previously untreated subjects with intermediate to very high-risk myelodysplastic syndromes (mds)
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429874/
http://dx.doi.org/10.1097/01.HS9.0000974892.81919.d4
work_keys_str_mv AT zeidanamerm pb2021phase2studyoforaldecitabinecedazuridineincombinationwithmagrolimabforpreviouslyuntreatedsubjectswithintermediatetoveryhighriskmyelodysplasticsyndromesmds
AT mosherkaren pb2021phase2studyoforaldecitabinecedazuridineincombinationwithmagrolimabforpreviouslyuntreatedsubjectswithintermediatetoveryhighriskmyelodysplasticsyndromesmds
AT souzasonia pb2021phase2studyoforaldecitabinecedazuridineincombinationwithmagrolimabforpreviouslyuntreatedsubjectswithintermediatetoveryhighriskmyelodysplasticsyndromesmds
AT mirakhurbeloo pb2021phase2studyoforaldecitabinecedazuridineincombinationwithmagrolimabforpreviouslyuntreatedsubjectswithintermediatetoveryhighriskmyelodysplasticsyndromesmds
AT keerharold pb2021phase2studyoforaldecitabinecedazuridineincombinationwithmagrolimabforpreviouslyuntreatedsubjectswithintermediatetoveryhighriskmyelodysplasticsyndromesmds
AT taylorjason pb2021phase2studyoforaldecitabinecedazuridineincombinationwithmagrolimabforpreviouslyuntreatedsubjectswithintermediatetoveryhighriskmyelodysplasticsyndromesmds

Ejemplares similares